Aimmune Receives Positive CHMP Opinion on PALFORZIA® for the Treatment of Patients with Peanut Allergy in Europe


Final European Commission Decision on Marketing Approval Anticipated in Q4 2020 Final European Commission Decision on Marketing Approval Anticipated in Q4 2020

See the original post here:
Aimmune Receives Positive CHMP Opinion on PALFORZIA® for the Treatment of Patients with Peanut Allergy in Europe

Related Posts